Skip to content
HowShorted

Evofem Biosciences, Inc. short interest in 2021

In 2021, Evofem Biosciences, Inc.'s disclosed short interest ran from 12.79% of shares outstanding on 15 Jan 2021 to 15.58% on 31 Dec 2021, a change of +2.79 percentage points. The year's high was 27.92% on 30 Jun 2021 and its low 10.52% on 28 May 2021, averaging 16.41% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 14.03 days on 29 Oct 2021. Full history: Evofem Biosciences, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022

Aggregate net short position time series for Evofem Biosciences, Inc. in 2021

2021 in figures

Start of year
12.79% (15 Jan 2021)
End of year
15.58% (31 Dec 2021)
Change
+2.79 pp
High
27.92% (30 Jun 2021)
Low
10.52% (28 May 2021)
Average
16.41%
Highest days to cover
14.03 (29 Oct 2021)
SEC filings marked
9

Every report in 2021

Evofem Biosciences, Inc. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 202112.79%4.64
29 Jan 202111.70%3.62
12 Feb 202111.61%1.87
26 Feb 202111.57%1.64
15 Mar 202110.99%1.5810-K filed, results (8-K)
31 Mar 202111.35%1.83
15 Apr 202114.85%4.11
30 Apr 202111.75%3.53
14 May 202111.14%2.8610-Q filed, results (8-K)
28 May 202110.52%1.00
15 Jun 202124.22%1.00
30 Jun 202127.92%2.62
15 Jul 202127.30%6.07
30 Jul 202127.46%8.54
13 Aug 202117.93%4.6210-Q filed, results (8-K)
31 Aug 202117.32%5.70
15 Sep 202118.29%8.99
30 Sep 202117.87%12.64
15 Oct 202117.75%10.82
29 Oct 202117.45%14.03results (8-K)
15 Nov 202116.35%8.8710-Q filed, results (8-K)
30 Nov 202115.01%5.22
15 Dec 202115.07%8.76
31 Dec 202115.58%5.51

See also: Evofem Biosciences, Inc.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.